Market Place
Sourcing Support
Flagship-founded Axcella folds
05 Dec 2023 //
FIERCE BIOTECH
Axcella Announces Reverse Stock Split Effective September 19, 2023
14 Sep 2023 //
BUSINESSWIRE
Axcella Granted Patent for Long COVID Fatigue Treatment
29 Aug 2023 //
BUSINESSWIRE
Axcella Reports Second Quarter Financial Results and Provides Business Update
03 Aug 2023 //
BUSINESSWIRE
Axcella Reports First Quarter Financial Results and Provides Business Update
04 May 2023 //
BUSINESSWIRE
Axcella Reports 4Q and Full Reports Full 2022 FYR and Provides Business Update
30 Mar 2023 //
BUSINESSWIRE
Axcella Announces FDA IND Clearance Supporting Path to Registration of AXA1125
15 Feb 2023 //
BUSINESSWIRE
Axcella seeks `light speed` swing at long Covid, but needs cash
24 Jan 2023 //
ENDPTS
Axcella Announces Regulatory Path to Registration of AXA1125 for COVID Fatigue
24 Jan 2023 //
BUSINESSWIRE
Axcella reduces workforce by 85%, prioritizes long Covid drug research
16 Dec 2022 //
ENDPTS
Axcella to Present at the AASLD Annual Meeting
03 Nov 2022 //
BUSINESSWIRE
Axcella Reports Third Quarter Financial Results and Provides Business Update
01 Nov 2022 //
BUSINESSWIRE
Axcella touts interim NASH data but needs cash to stay afloat
29 Sep 2022 //
ENDPTS
With cash dwindling, Axcella shares look at blinded NASH data
29 Sep 2022 //
FIERCEBIOTECH
Axcella to Participate in the H.C. Wainwright Global Investment Conference
12 Sep 2022 //
BUSINESSWIRE
Axcella Reports Second Quarter Financial Results and Provides Business Update
12 Aug 2022 //
BUSINESSWIRE
Axcella flunks long Covid PhII primary goal -- but plots a path into PhIII
03 Aug 2022 //
ENDPTS
Axcella CEO hits Washington to drum up support for long COVID
21 Jun 2022 //
FIERCEBIOTECH
Axcella Announces Completion of Enrollment of Clinical Trial for Long COVID
26 May 2022 //
BUSINESSWIRE
Flagship-backed Axcella drops PhII program as it focuses on long Covid, NASH
26 May 2022 //
ENDPTS
Axcella Therapeutics to Participate in the H.C. Wainwright Conference
19 May 2022 //
BUSINESSWIRE
Axcella Reports First Quarter Financial Results and Provides Business Update
05 May 2022 //
BUSINESSWIRE
Axcella Reports Fourth Quarter and Full Year 2021 Financial Results
30 Mar 2022 //
BUSINESSWIRE
Axcella to Report Q4 and Year End 2021 Financial Results on March 30, 2022
23 Mar 2022 //
BUSINESSWIRE
Axcella Tx says $25 M Registered Direct Offering of Common Stock Priced
16 Mar 2022 //
BUSINESSWIRE
Axcella Therapeutics Announces FDA FTD for AXA1125 in NASH
14 Feb 2022 //
BUSINESSWIRE
Axcella Therapeutics Announces Appointment of New Chief Financial Officer
07 Feb 2022 //
BUSINESSWIRE
Axcella to Participate in Piper Sandler 33rd Annual Healthcare Conference
18 Nov 2021 //
BUSINESSWIRE
Axcella jumps into long COVID with phase 2 of midstage NASH drug
27 Oct 2021 //
BIOSPACE
Axcella commences trial of AXA1125 for Long Covid treatment
26 Oct 2021 //
CLINICALTRIALSARENA
Axcella Announces Publication in AJG on AXA1125-003
16 Aug 2021 //
BUSINESSWIRE
Axcella Reports Second Quarter Financial Results and Provides Business Update
29 Jul 2021 //
BUSINESSWIRE
Axcella to Report Second Quarter 2021 Financial Results on July 29, 2021
22 Jul 2021 //
BUSINESSWIRE
Axcella Announces Initiation of EMMPOWER? Phase 2 Clinical Trial of AXA1665
30 Jun 2021 //
BUSINESSWIRE
Positive Clinical Data About Axcella’s AXA1665 Candidate for Overt Hepatic
24 May 2021 //
BUSINESSWIRE
Axcella Announces Initiation of EMMPACT? Phase 2b Clinical Trial of AXA1125
11 May 2021 //
BUSINESSWIRE
Axcella Announces Initiation of EMMPACT? Phase 2b Clinical Trial of AXA1125
11 May 2021 //
BUSINESSWIRE
Axcella Announces Upcoming Oral Presentation at Digestive Disease Week (DDW) 202
22 Apr 2021 //
BUSINESSWIRE
Axcella Announces AXA1125’s IND Clearance for the Treatment of NASH
14 Apr 2021 //
BUSINESSWIRE
Axcella Announces AXA1125’s IND Clearance for the Treatment of NASH
13 Apr 2021 //
BUSINESSWIRE
Axcella Announces Upcoming Presentations at NASH-TAG 2021
25 Feb 2021 //
BUSINESSWIRE
Axcella Announces Upcoming Presentations at NASH-TAG 2021
24 Feb 2021 //
BUSINESSWIRE
Axcella Announces IND Clearance for AXA1665, Program Updates and 2021 Milestones
11 Jan 2021 //
BUSINESSWIRE
Axcella Announces Upcoming Presentation at J.P. Morgan Healthcare Conference
04 Jan 2021 //
BUSINESSWIRE
Axcella Announces Upcoming Presentations at AASLD’s The Liver Meeting® 2020
02 Oct 2020 //
BUSINESSWIRE
Axcella Announces Upcoming Investor Conference Presentation
29 Sep 2020 //
BUSINESSWIRE
Axcella’s Late-Breaker Data from AXA1125-003 Study Presented at the EASL
27 Aug 2020 //
BUSINESSWIRE
Results of Axcella’s AXA1665-001 Clinical Study Published Clinical Translational
17 Aug 2020 //
BUSINESSWIRE
Results of Axcella’s AXA1665-001 Clinical Study Published
17 Aug 2020 //
BUSINESSWIRE
Axcella Reports Positive Top-Line Data from AXA1665-002 & Second Quarter Results
05 Aug 2020 //
BIOSPACE
Axcella Reports Positive Top-Line Data from AXA1665-002 Second Quarter Results
04 Aug 2020 //
BUSINESSWIRE
Axcella Announces Patent Issuances Covering AXA1665
17 Jun 2020 //
BUSINESSWIRE
Axcella Announces Patent Issuances Covering AXA1665
17 Jun 2020 //
BUSINESSWIRE
Axcella Announces Closing of PO of Common Stock, Including Full Exercise
18 May 2020 //
BUSINESSWIRE
Axcella Announces Pricing of Public Offering of Common Stock
13 May 2020 //
BUSINESSWIRE
Axcella announces positive results from study of NAFLD treatment
07 May 2020 //
CLINICALTRIALSARENA
Axcella Announces Positive Top-Line Data from AXA1125-003 Clinical Study
06 May 2020 //
BUSINESSWIRE
Another sparse round of NASH data; TG raises $60M after PhIII success
06 May 2020 //
ENDPTS
Axcella to Report Top-Line Data from AXA1125-003 in Adult Subjects with NAFLD
05 May 2020 //
BUSINESSWIRE
Axcella Completes Enrollment of Subjects in AXA1665-002 Study
26 Feb 2020 //
BUSINESSWIRE
